Document Detail


Musculoskeletal manifestations and autoimmune diseases related to new biologic agents.
MedLine Citation:
PMID:  16344625     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: The anti-tumor necrosis factor agents are now widely used in the management of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile inflammatory arthritis. One of the most common observations made during their use is the development of autoantibodies. The purpose of this paper is to review this phenomenon and its clinical implications.
RECENT FINDINGS: While the development of different autoantibodies is a common encounter, rare cases of lupus-like syndromes have been reported. On the other hand, a variety of immune-mediated clinical manifestations have been described, including vasculitis and demyelinating syndromes. Rare cases of cytopenia and non-specific lung injuries have also been reported.
SUMMARY: While these clinical complications are rare and isolated events, clinicians must be aware of their occurrence. The experience with the anti-tumor necrosis factor agents is rather short and new, unusual immune-mediated complications may still appear. Clinicians should be prepared to recognize them.
Authors:
Boulos Haraoui; Edward Keystone
Related Documents :
3327645 - Polychondritis and rheumatoid arthritis. case report and review of the literature.
21097565 - A review of the use of mobile phone text messaging in clinical and healthy behaviour in...
24095065 - Arthroscopy of the hip: factors affecting outcome.
20919445 - Capd peritonitis after colonoscopy: follow the guidelines.
12000395 - Does hermansky-pudlak syndrome predispose to systemic lupus erythematosus?
24093025 - Xanthogranulomatous appendicitis in a child: report of a case and review of the literat...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in rheumatology     Volume:  18     ISSN:  1040-8711     ISO Abbreviation:  Curr Opin Rheumatol     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-13     Completed Date:  2006-04-04     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9000851     Medline TA:  Curr Opin Rheumatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  96-100     Citation Subset:  IM    
Affiliation:
Université de Montréal, RDU CHUM, Hôpital Notre-Dame, Montreal, Quebec, Canada. paulharaoui@attglobal.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / adverse effects*
Arthritis, Rheumatoid / drug therapy
Autoantibodies / immunology
Autoimmune Diseases / immunology*
Biological Therapy / adverse effects*
Humans
Immunoglobulin G / adverse effects
Lupus Erythematosus, Systemic / chemically induced,  immunology
Musculoskeletal Diseases / immunology*
Receptors, Tumor Necrosis Factor
Vasculitis / chemically induced,  immunology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Autoantibodies; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Musculoskeletal and autoimmune manifestations of HIV, syphilis and tuberculosis.
Next Document:  Celiac sprue (the great modern-day imposter).